Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.

ABSTRACT:

Background

Treatment options are limited for patients with thymic carcinoma. These aggressive tumours are not typically associated with paraneoplastic autoimmune disorders, and strong PD-L1 expression has been reported in thymic epithelial tumours. We aimed to assess the activity of pembrolizumab, a monoclonal antibody that targets PD-1, in patients with advanced thymic carcinoma.

Methods

We completed a single-arm phase 2 study of pembrolizumab in patients with recurrent thymic carcinoma who had progressed after at least one line of chemotherapy. This was a single-centre study performed at Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. Key inclusion criteria were an Eastern Cooperative Oncology Group performance status of 0-2, no history of

SUBMITTER: Giaccone G 

PROVIDER: S-EPMC10683856 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature